Cost effectiveness of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia: A Single-Center retrospective cohort study

• Hoofdauteurs: Yazed AlRuthia (Auteur), Bushra Q. AlOtaibi (Auteur), Reem M. AlOtaibi (Auteur), Najla Q. AlOtaibi (Auteur), Miteb Alanazi (Auteur), Ghadah Asaad Assiri (Auteur)
• Formaat: Boek
• Gepubliceerd in: Elsevier, 2023-01-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Background: Rivaroxaban is a novel oral anticoagulant (NOAC) that is commonly used for stroke prevention among patients with atrial fibrillation (AF). However, its cost effectiveness in reducing the risk of hospitalization and mortality in comparison to warfarin among nonvalvular AF patients in Saud...